MesotheliomaCenter's

Mesothelioma-Line

Curated Journal Articles on Mesothelioma

Category Archives: Immunohistochemistry or IHC

Often used to diagnose cancer, Immunohistochemistry or IHC is a process by which antibodies are detected in tissue samples by use of a specific antigen or antigens. IHC is also widely used in basic research to understand the distribution and localization of biomarkers in different parts of a tissue (also see “Serum Marker/Blood Test“).

The Investigation of Lipoxygenases as Therapeutic Targets in Malignant Pleural Mesothelioma.

Pathology Oncology Research 2019 April 2 [Link] Oguh-Olayinka L, Agarwal V, Ranatunge D, Campbell A, Laufer S, Cawkwell L, Lind MJ Abstract Advanced malignant pleural mesothelioma (MPM) has an extremely poor prognosis with limited chemotherapy options, therefore the identification of new therapeutic targets would aid in disease management. Arachidonic acid is metabolised by cyclooxygenase and […]

Comments Off on The Investigation of Lipoxygenases as Therapeutic Targets in Malignant Pleural Mesothelioma.

Significance of EGFR and PTEN Expression and PLR and NLR for Predicting the Prognosis of Epithelioid Malignant Peritoneal Mesothelioma.

Liang Y, Zheng G, Yin W, Song H, Li C, Tian L, Yang D Abstract OBJECTIVE: The aim of our study was to investigate the expression of EGFR and PTEN in tissues and measure the serum platelet-to-lymphocyte ratio (PLR) and neutrophil-to-lymphocyte ratio (NLR) to evaluate the prognostic factors of patients with epithelioid malignant peritoneal mesothelioma […]

Comments Off on Significance of EGFR and PTEN Expression and PLR and NLR for Predicting the Prognosis of Epithelioid Malignant Peritoneal Mesothelioma.

Tumour infiltrating lymphocytes and PD-L1 expression as potential predictors of outcome in patients with malignant pleural mesothelioma.

Molecular Biology Reports 2019 March 6 [Link] Sobhani N, Roviello G, Pivetta T, Ianza A, Bonazza D, Zanconati F, Giudici F, Bottin C, Corona SP, Guglielmi A, Rizzardi C, Milione M, Cortale M, Confalonieri M, Generali D Abstract Malignant pleural mesothelioma (MPM) is a rare and aggressive form of tumour. Some mesotheliomas have been proven […]

Comments Off on Tumour infiltrating lymphocytes and PD-L1 expression as potential predictors of outcome in patients with malignant pleural mesothelioma.

About the diagnostic value of BAP-1 antibody in malignant pleural mesothelioma: a meta-analysis.

Journal of Immunoassay & Immunochemistry 2019 February 27 [Link] Mlika M, Zorgati M, BenKhelil M, Mezni FE Abstract BACKGROUND: The positive diagnosis of MPM is based on morphologic features coupled with immunohistochemical findings. Many antibodies have been published especially in order to differentiate between malignant tumors and atypical mesothelial hyperplasia. BAP-1 is a BRCA1-binding protein […]

Comments Off on About the diagnostic value of BAP-1 antibody in malignant pleural mesothelioma: a meta-analysis.

Tumor PD-L1 expression in malignant pleural and peritoneal mesothelioma by Dako PD-L1 22C3 pharmDx and Dako PD-L1 28-8 pharmDx assays.

Human Pathology 2019 February 19 [Link] Chapel DB, Stewart R, Furtado LV, Husain AN, Krausz T, Deftereos G Abstract Malignant mesothelioma (MM) is an aggressive neoplasm with poor prognosis. The Dako PD-L1 22C3 and 28-8 pharmDx assays are approved by the US Food and Drug Administration (FDA) as companion and complementary diagnostics for the anti-PD-1 […]

Comments Off on Tumor PD-L1 expression in malignant pleural and peritoneal mesothelioma by Dako PD-L1 22C3 pharmDx and Dako PD-L1 28-8 pharmDx assays.

Use of Immune Checkpoint Inhibitors in Mesothelioma.

Current Treatment Options in Oncology 2019 February 14 [Link] Forde PM, Scherpereel A, Tsao AS Abstract Recent advances in immunology have extended into the mesothelioma field. To date, only Japan has given regulatory approval to salvage nivolumab in chemo-refractory mesothelioma patients. The USA has included in the NCCN guidelines that pembrolizumab (in programmed death ligand […]

Comments Off on Use of Immune Checkpoint Inhibitors in Mesothelioma.

Tenascin XB Is a Novel Diagnostic Marker for Malignant Mesothelioma.

Anticancer Research 2019 February [Link] Nakayama K, Seike M, Noro R, Takeuchi S, Matsuda K, Kunugi S, Kubota K, Gemma A Abstract BACKGROUND/AIM: Malignant mesothelioma (MM) is an aggressive tumor with poor prognosis. The establishment of a new diagnostic and therapeutic approach for MM is expected. This study investigated the diagnostic significance of tenascin XB […]

Comments Off on Tenascin XB Is a Novel Diagnostic Marker for Malignant Mesothelioma.

Inhibition of collagen production delays malignant mesothelioma tumor growth in a murine model.

Biochemical and Biophysical Research Communications 2019 March 5 [Link] Abayasiriwardana KS, Wood MK, Prêle CM, Birnie KA, Robinson BW, Laurent GJ, McAnulty RJ, Mutsaers SE Abstract Malignant mesothelioma is an aggressive fibrous tumor, predominantly of the pleura, with a very poor prognosis. Cell-matrix interactions are recognized important determinants of tumor growth and invasiveness but the […]

Comments Off on Inhibition of collagen production delays malignant mesothelioma tumor growth in a murine model.

BAP1 Loss is a Useful Adjunct to Distinguish Malignant Mesothelioma Including the Adenomatoid-like Variant From Benign Adenomatoid Tumors.

Applied Immunohistochemistry & Molecular Morphology 2019 January 11 [Link] Erber R, Warth A, Muley T, Hartmann A, Herpel E, Agaimy A Abstract Malignant mesothelioma (MM) can show areas closely mimicking reactive mesothelial proliferations or recapitulating benign adenomatoid tumors (ATs) making distinction on occasion impossible on morphologic ground alone, particularly in limited biopsy material. Recently, loss […]

Comments Off on BAP1 Loss is a Useful Adjunct to Distinguish Malignant Mesothelioma Including the Adenomatoid-like Variant From Benign Adenomatoid Tumors.

Molecular pathways and diagnosis in malignant mesothelioma: A review of the 14th International Conference of the International Mesothelioma Interest Group.

Lung Cancer 2019 January [Link] Chapel DB, Churg A, Santoni-Rugiu , Tsujimura T4, Hiroshima K5, Husain AN Abstract The pathologist plays a central role in the diagnosis and management of malignant mesothelioma, including definitive tissue-based diagnosis in conjunction with clinical and radiographic data; diverse ancillary studies of diagnostic, prognostic, and predictive importance; and research efforts to better define the pathobiology of […]

Comments Off on Molecular pathways and diagnosis in malignant mesothelioma: A review of the 14th International Conference of the International Mesothelioma Interest Group.